Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease

NCT03495973 · clinicaltrials.gov ↗

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Ustekinumab

Sponsor

Janssen-Cilag Ltd.